Premium Content Regulatory alerts

Entyvio® accepted for moderately to severely active Crohn's disease (restricted)

Restricted to patients who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist.

Please sign in or register for FREE

No comments yet.